Nautilus Biotechnology Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $190.000K
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 8.33 percent increase over losses of $(0.12) per share
Nautilus lost less money per share than experts thought it would, which is like doing better than a bad grade people predicted. When a company loses less money than expected, it can mean their business plan is working better than feared.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.